Fig. 1From: Treatment adherence and persistence with long-acting somatostatin analog therapy for the treatment of acromegaly: a retrospective analysisPatient selection. *Pegvisomant was excluded from the analysis because it is not a somatostatin analog and the mode of treatment (daily injection) was not considered comparable to that of octreotide and lanreotide (monthly injection) for this studyBack to article page